Summit Therapeutics (SMMT) Intangibles (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly Intangibles came in at $8.0 million in Q3 2022, down 25.04% YoY from $10.6 million in Q3 2021, and down 10.65% on a QoQ basis from $8.9 million in Q2 2022.
Summit Therapeutics (SMMT) Intangibles (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of Intangibles data on file, last reported at $8.0 million in Q3 2022.
- Quarterly Intangibles fell 25.04% year-over-year to $8.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $8.0 million (down 25.04% YoY) and the FY2021 annual result came in at $10.4 million, down 9.69% from the prior year.
- Intangibles declined to $8.0 million in Q3 2022, from $8.9 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $20.4 million in Q2 2018 to a low of $4.4 million in Q3 2018.
- A 5-year average of $12.0 million and a median of $11.4 million in 2020 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2018 — Intangibles soared 362.63% — and 2019, when it slumped 31.78%.
- Tracing SMMT's Intangibles over 5 years: stood at $14.1 million in 2018, then decreased by 9.0% to $12.8 million in 2019, then decreased by 9.99% to $11.5 million in 2020, then decreased by 9.69% to $10.4 million in 2021, then decreased by 23.53% to $8.0 million in 2022.
- The last three Intangibles figures came in at $8.0 million (Q3 2022), $8.9 million (Q2 2022), and $9.9 million (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 7.95 Mn |
| Jun 30, 2022 | 8.90 Mn |
| Mar 31, 2022 | 9.87 Mn |
| Dec 31, 2021 | 10.40 Mn |
| Sep 30, 2021 | 10.61 Mn |
| Jun 30, 2021 | 11.16 Mn |
| Mar 31, 2021 | 11.36 Mn |
| Dec 31, 2020 | 11.52 Mn |
| Sep 30, 2020 | 11.10 Mn |
| Mar 31, 2020 | 12.65 Mn |
| Dec 31, 2019 | 12.79 Mn |
| Oct 31, 2019 | 12.48 Mn |
| Jul 31, 2019 | 13.05 Mn |
| Jan 31, 2019 | 13.59 Mn |
| Oct 31, 2018 | 14.06 Mn |
| Jul 31, 2018 | 4.40 Mn |
| Apr 30, 2018 | 20.44 Mn |
| Jan 31, 2018 | 19.93 Mn |
| Jan 31, 2017 | 4.31 Mn |